JP2013521497A5 - - Google Patents

Download PDF

Info

Publication number
JP2013521497A5
JP2013521497A5 JP2012556133A JP2012556133A JP2013521497A5 JP 2013521497 A5 JP2013521497 A5 JP 2013521497A5 JP 2012556133 A JP2012556133 A JP 2012556133A JP 2012556133 A JP2012556133 A JP 2012556133A JP 2013521497 A5 JP2013521497 A5 JP 2013521497A5
Authority
JP
Japan
Prior art keywords
xid
hcv
subject
specimen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012556133A
Other languages
English (en)
Japanese (ja)
Other versions
JP6095984B2 (ja
JP2013521497A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/026455 external-priority patent/WO2011109285A2/en
Publication of JP2013521497A publication Critical patent/JP2013521497A/ja
Publication of JP2013521497A5 publication Critical patent/JP2013521497A5/ja
Application granted granted Critical
Publication of JP6095984B2 publication Critical patent/JP6095984B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012556133A 2010-03-01 2011-02-28 Hcv感染患者のクリオグロブリン血症性血管炎およびb細胞悪性腫瘍のための予後マーカー Expired - Fee Related JP6095984B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30916110P 2010-03-01 2010-03-01
US61/309,161 2010-03-01
PCT/US2011/026455 WO2011109285A2 (en) 2010-03-01 2011-02-28 Prognostic marker for cryoglobulinemic vasculitis and b cell malignancies in hcv infected patients

Publications (3)

Publication Number Publication Date
JP2013521497A JP2013521497A (ja) 2013-06-10
JP2013521497A5 true JP2013521497A5 (https=) 2014-04-24
JP6095984B2 JP6095984B2 (ja) 2017-03-15

Family

ID=44542788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012556133A Expired - Fee Related JP6095984B2 (ja) 2010-03-01 2011-02-28 Hcv感染患者のクリオグロブリン血症性血管炎およびb細胞悪性腫瘍のための予後マーカー

Country Status (7)

Country Link
US (3) US9719141B2 (https=)
EP (1) EP2542892A4 (https=)
JP (1) JP6095984B2 (https=)
AU (1) AU2011223906B2 (https=)
BR (1) BR112012021795A2 (https=)
CA (1) CA2791676A1 (https=)
WO (1) WO2011109285A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103184216B (zh) * 2011-12-27 2015-03-18 深圳华大基因科技有限公司 用于扩增免疫球蛋白重链cdr3编码序列的引物组合物及其用途
US11781112B2 (en) 2016-03-06 2023-10-10 Kareem Thomas Robinson Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines
RU2642626C1 (ru) * 2016-11-03 2018-01-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ прогнозирования развития криоглобулинемического васкулита у больных хроническим гепатитом с
AU2018313853A1 (en) 2017-08-08 2020-01-02 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020049A1 (it) 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
US8178303B2 (en) 2003-12-04 2012-05-15 Wake Forest University Health Sciences Increasing the speed of cryoglobulin precipitation
EP1801116A1 (en) 2005-12-21 2007-06-27 F. Hoffmann-La Roche Ag HCV replicon shuttle vectors

Similar Documents

Publication Publication Date Title
ES2730980T3 (es) Método de evaluación de la inmunodiversidad y su uso
AU2009240021B2 (en) Antiviral therapy
WO2010017515A2 (en) Breast cancer specific markers and methods of use
JP6092655B2 (ja) テスト体液サンプルの分類方法
CN107541563B (zh) 一种用于早期诊断、预测脓毒血症并发急性肾损伤的分子标记物、试剂盒及应用
McArdle et al. Discovery proteomics for COVID-19: where we are now
JP2019528455A (ja) 新規な肝硬変または肝線維症のマーカー
CN109337909B (zh) 一种检测肝癌耐药细胞株的核酸适体及其应用
JP2006518991A5 (https=)
CN107267649B (zh) Stradb在哮喘早期诊断中的应用
RU2013113314A (ru) Способы выявления антител против не4 и способы диагностики и/или прогнозирования состояний, ассоциированных с экспрессирующими не4 клетками
Young et al. A triad of somatic mutagenesis converges in self-reactive B cells to cause a virus-induced autoimmune disease
CN107164536B (zh) Mrnip基因在重度抑郁症诊断中的应用
JP2013521497A5 (https=)
CN107488737A (zh) 一种检测外周血tcr可变区编码基因的液体活检试剂盒及其应用
Knight et al. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies
CN108796074B (zh) 检测环状RNA circRNF13的试剂在制备肿瘤辅助诊断制剂上的应用及试剂盒
CN120485376B (zh) 一种用于辅助诊断肠癌的eRNA分子标记物及其应用
JP6095984B2 (ja) Hcv感染患者のクリオグロブリン血症性血管炎およびb細胞悪性腫瘍のための予後マーカー
CN105648075A (zh) 一种肝癌诊断组合及含有该组合的试剂盒
CN118879851A (zh) 肺动脉高压相关的plekhh2基因突变及其应用
US20230133776A1 (en) Methods for diagnosing cancer
CN102021169A (zh) 一种血清/血浆miRNA组合物及其应用
CN106957905A (zh) 一种用于评估肿瘤免疫治疗效果的分子检测方法及引物组合物及试剂盒
CN108676880B (zh) 一种人血清afp阴性肝细胞癌检测试剂盒